Abstract: A reversible recording medium according to an embodiment of the present disclosure includes: a recording layer including a leuco pigment as a coloring compound; and a first barrier film that is provided on one surface and a side surface of the recording layer and suppresses mixing of at least one of water or oxygen.

Abstract: A viewing angle-controlling liquid crystal panel sequentially includes a first polarizing plate; a first liquid crystal panel; a second polarizing plate; a second liquid crystal panel; and a third polarizing plate, wherein an azimuthal angle ?P1 of the absorption axis of the first polarizing plate, an azimuthal angle ?1 of a director of liquid crystal molecules near the first substrate and an azimuthal angle ?2 of a director of liquid crystal molecules near the second substrate in the first liquid crystal panel, an azimuthal angle ?P2 of the absorption axis of the second polarizing plate, an azimuthal angle ?3 of a director of liquid crystal molecules near the third substrate and an azimuthal angle ?4 of a director of liquid crystal molecules near the fourth substrate in the second liquid crystal panel, and an azimuthal angle ?P3 of the absorption axis of the third polarizing plate satisfy specific formulas.

Abstract: A viewing angle-controlling liquid crystal panel sequentially includes a first polarizing plate; a first liquid crystal panel; a second polarizing plate; a second liquid crystal panel; and a third polarizing plate, wherein an azimuthal angle ?P1 of the absorption axis of the first polarizing plate, an azimuthal angle ?1 of a director of liquid crystal molecules near the first substrate and an azimuthal angle ?2 of a director of liquid crystal molecules near the second substrate in the first liquid crystal panel, an azimuthal angle ?P2 of the absorption axis of the second polarizing plate, an azimuthal angle ?3 of a director of liquid crystal molecules near the third substrate and an azimuthal angle ?4 of a director of liquid crystal molecules near the fourth substrate in the second liquid crystal panel, and an azimuthal angle ?P3 of the absorption axis of the third polarizing plate satisfy specific formulas.

Abstract: A specimen image registration according to the invention includes selecting at least one third image different from a first image and a second image which are target images from the plurality of specimen images, obtaining a registration amount between the first image and the third image and a registration amount between the second image and the third image, and obtaining a registration amount between the first image and the second image based on the registration amount between the first image and the third image and the registration amount between the second image and the third image. It is possible to improve a success rate of registration even if the specimen images obtained by a plurality of types of staining are largely different in stained state.

Abstract: Provided is a liquid crystal display device including a liquid crystal panel including in the following order an active matrix substrate, a liquid crystal layer, and a counter substrate. The active matrix substrate includes in the following order a first electrode and a second electrode including a first linear electrode portion extending in a first direction. The counter substrate includes a third electrode including second linear electrode portions extending in a second direction crossing the first direction, and a fourth electrode including an island-shaped electrode portion as a floating electrode. The island-shaped electrode portion is disposed between the second linear electrode portions in a plan view, overlaps an optical aperture of one of two pixels adjacent to each other along the second direction, and does not overlap an optical aperture of the other of the two pixels.

Abstract: A filter element, in particular an air filter element, has a filter media body surrounding a hollow interior and has a first end and an opposite second end. A first end cap is positioned on the first end of the filter media body, and a second end cap is positioned on the second end of the filter media body. The second end cap is a closed end cap. The second end cap has a plurality of spaced-apart inner adapter projections arranged thereon and projecting in direction of a central axis away from the first end cap. At least some of the inner adapter projections are positioned in a circular arrangement so as to surround a center of the second end cap. Such a filter element is arranged in a housing of a filter system provided with a receiver arrangement for the filter element.

Abstract: A method for reducing the content of a saturated hydrocarbon in oils and/or fats. The method includes subjecting raw material oils and/or fats to a short path distillation treatment under a temperature condition of 50° C. or higher and 270° C. or lower. In the short path distillation treatment, a feed rate of the raw material oils and/or fats to a short path distillation apparatus may be 30.0 kg/h·m2 or less per unit area of an evaporation surface of the short path distillation apparatus. The feed rate may be 5.00 kg/h·m2 or more and 25.0 kg/h·m2 or less per unit area of an evaporation surface of the short path distillation apparatus.

Abstract: Provided is a novel combination therapy that exhibits excellent antitumor effects, and that uses an FGFR-inhibiting compound and an MEK inhibitor. An antitumor agent contains (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient and is administered in combination with an MEK inhibitor.

Abstract: A pharmaceutical composition for treating cartilage dysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, and a treatment method using the pharmaceutical composition.

Abstract: The present invention provides a method of producing a refined oil and/or fat, comprising step B: a step of steam-distilling a raw material oil and/or fat at 240° C. or more, wherein a content of saturated hydrocarbons having 20 to 35 carbon atoms in the refined oil and/or fat is 10 ppm by mass or less.

Abstract: The present invention provides a pharmaceutical composition for treating a patient with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof as an active ingredient; and a therapeutic method using the pharmaceutical composition.

Abstract: The problem to be solved by the present disclosure is to provide a novel combination therapy using (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof, the combination therapy exhibiting an excellent antitumor effect on cancer patients with resistance to immune checkpoint inhibitors. The present disclosure provides an antitumor agent comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient, the antitumor agent being administered in combination with pembrolizumab to a cancer patient with resistance to immune checkpoint inhibitors.

Abstract: The problem to be solved by the present disclosure is to provide a novel combination therapy using (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof, the combination therapy exhibiting an excellent antitumor effect on cancer patients with resistance to immune checkpoint inhibitors. The present disclosure provides an antitumor agent comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient, the antitumor agent being administered in combination with an immune checkpoint inhibitor, except for pembrolizumab, to a cancer patient with resistance to immune checkpoint inhibitors.

Abstract: Provided is a novel treatment method for cancer tumors to which endocrine therapy is to be applied, using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof for use in treatment and/or prevention of tumors to which endocrine therapy is to be applied, the pharmaceutical composition being used in combination with endocrine therapy, as well as its related compound, use, method, and combination.

Abstract: Provided is an effective method for using an orally administrable compound having an excellent Aurora A selective inhibitory effect, and a microtubule-targeting drug in combination. The present invention provides a method for treatment of malignant tumor by a combination of 1-(2,3-dichlorobenzoyl)-4-[5-fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2-yl]methyl-4-piperidinecarboxylic acid (compound I) or a salt thereof and a microtubule-targeting drug, wherein the following administration schedule thereof is performed: one cycle involves 7 days; the microtubule-targeting drug is administered once; and the compound I or the salt thereof is administered for 3 consecutive days with cessation of the drug for remaining 4 days.

Abstract: The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.

Abstract: A method for reducing the content of a saturated hydrocarbon in oils and/or fats. The method includes subjecting raw material oils and/or fats to a short path distillation treatment under a temperature condition of 50° C. or higher and 270° C. or lower. In the short path distillation treatment, a feed rate of the raw material oils and/or fats to a short path distillation apparatus may be 30.0 kg/h·m2 or less per unit area of an evaporation surface of the short path distillation apparatus. The feed rate may be 5.00 kg/h·m2 or more and 25.0 kg/h·m2 or less per unit area of an evaporation surface of the short path distillation apparatus.

Abstract: The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.

Abstract: The problem to be solved by the present invention is to provide a potent and highly selective novel FGFR inhibitor, and an antitumor agent having reduced side effects, such as increased blood phosphorus levels, while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) or a salt thereof that is used so that the 3,5-disubstituted benzene alkynyl compound or a salt thereof is administered on an administration schedule of at least twice a week and a dosing interval of at least one day.

Abstract: A method for treating a tumor by combining a piperidine compound of formula (I) or salt thereof and a microtubule-targeting drug, in which the microtubule-targeting drug is administered once per 7 days or more one cycle, and the piperidine compound is administered once or more per day for 4 days or more: R1 represents a carboxyl group, —C(?O)NR5R6, or an oxadiazolyl group optionally substituted with a C1-C6 alkyl group or trifluoromethyl group; R2 represents a halogen atom or C1-C6 alkoxy group; R3 represents a phenyl group optionally having 1 to 3 groups, selected from a halogen atom, and a C1-C6 alkyl, C1-C6 alkoxy, or trifluoromethyl group; R4 represents a hydrogen atom or C1-C6 alkyl group; and R5 and R6, each represent a hydrogen atom, a C1-C6 alkyl or C3-C6 cycloalkyl group; or R5 and R6, together with a nitrogen atom, optionally form a 3 to 6-membered nitrogen-containing saturated heterocyclic group.